Travere Therapeutics, Inc., (Nasdaq: TVTX) announced that today the U.S. Food and Drug Administration (FDA) has extended the review timeline of its supplemental New Drug Application (sNDA) for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback